Consolidated guideline on sexual and reproductive health and rights of women living with HIV

Executive summary

An integrated approach to health and human rights lies at the heart of ensuring the dignity and well-being of women living with HIV.

HIV is not only driven by gender inequality, but it also entrenches gender inequality, leaving women more vulnerable to its impact. Providing sexual and reproductive health interventions for women living with HIV that are grounded in principles of gender equality and human rights can have a positive impact on their quality of life; it is also a step towards long-term improved health status and equity.

Introduction

There were an estimated 17.8 million women aged 15 and older living with HIV in 2015, constituting 51% of all adults living with HIV. Adolescent girls and young women are particularly affected; in 2015 they constituted 60% of young people aged 15–24 years who were living with HIV, and they also accounted for 58% of newly acquired HIV infections among young persons in that age group. In many countries, women living with HIV do not have equitable access to good-quality health services and are also faced with multiple and intersecting forms of stigma and discrimination. Furthermore, women living with HIV are disproportionately vulnerable to violence, including violations of their sexual and reproductive rights.

Many significant changes in HIV-related policies, research and practice have occurred in the 10 years since the World Health Organization (WHO) published Sexual and reproductive health of women living with HIV/AIDS: guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings in 2006. These changes include the rapid expansion of antiretroviral therapy (ART) and the release in 2015 of WHO recommendations to offer immediate ART to all individuals living with HIV and to offer pre-exposure prophylaxis (PrEP) to individuals at substantial risk of HIV infection as an additional prevention choice. Given the significant difference in scope, this guideline was viewed as a new submission by the WHO Guidelines Review Committee, rather than an update of the 2006 guidelines. This guideline responds to requests from organizations, institutions and individuals for guidance which consolidates existing recommendations specific to women living with HIV along with new recommendations and good practice statements. It is expected to support front-line health-care providers, programme managers and public health policy-makers around the world to better address the sexual and reproductive health and rights (SRHR) of women living with HIV.

The starting point for this guideline is the point at which a woman has learnt that she is living with HIV, and it therefore covers key issues for providing comprehensive SRHR-related services and support for women living with HIV. As women living with HIV face unique challenges and human rights violations related to their sexuality and reproduction within their families and communities, as well as from the health-care institutions where they seek care, particular emphasis is placed on the creation of an enabling environment to support more effective health interventions and better health outcomes.
This guideline is meant to help countries to more effectively and efficiently plan, develop and monitor programmes and services that promote gender equality and human rights and hence are more acceptable and appropriate for women living with HIV, taking into account the national and local epidemiological context. It discusses implementation issues that health interventions and service delivery must address to achieve gender equality and support human rights.

This guideline aims to provide:

- **Evidence-based recommendations** for the SRHR of women living with HIV in all of their diversity, with a particular focus on settings where the health system has limited capacity and resources; and

- **Good practice statements** on key operational and service delivery issues that need to be addressed to (i) increase access to, uptake of, and the quality of outcomes of sexual reproductive health (SRH) services, (ii) improve human rights and (iii) promote gender equality for women living with HIV.

### A woman-centred approach

Woman-centred health services involve an approach to health care that consciously adopts the perspectives of women, their families and communities. This means that health services see women as active participants in, as well as beneficiaries of, trusted health systems that respond to women’s needs, rights and preferences in humane and holistic ways. Care is provided in ways that respect women’s autonomy in decision-making about their health, and services must include provision of information and options to enable women to make informed choices. The needs and perspectives of women, their families and communities are central to provision of care, and to the design and implementation of programmes and services. A woman-centred approach is underpinned by two guiding principles: promotion of human rights and gender equality.

### Guiding principles

**Human rights**: An integrated approach to health and human rights lies at the heart of ensuring the dignity and well-being of women living with HIV. This includes, but is not limited to, the right to the highest attainable standard of health; the right to life and physical integrity, including freedom from violence; the right to equality and non-discrimination on the basis of sex; and the right to freedom from torture or cruel, inhuman or degrading treatment. The right to SRH is an integral part of the right to health, enshrined in article 12 of the International Covenant on Economic, Social and Cultural Rights.

**Gender equality**: The promotion of gender equality is central to the achievement of SRHR of all women, including women living with HIV in all their diversity. This means recognizing and taking into account how unequal power in women’s intimate relationships, harmful gender norms and women’s lack of access to and control over resources affect their access to and experiences with health services.

### Guideline development methods

The WHO Department of Reproductive Health and Research (RHR) led the development of this consolidated guideline, following WHO procedures and reporting standards laid out in the 2014 *WHO handbook for guideline development*. To help ensure that the guidance appropriately reflects the concerns of women living with HIV in all their diversity, WHO commissioned a global survey on the SRHR priorities of women living with HIV – the Global Values and Preferences Survey (GVPS)\(^1\). This process was placed at the heart of the development of this guideline and the findings of the survey are included throughout the guideline.

To develop the scope of this guideline, the WHO Guideline Steering Group (SG) mapped all existing WHO SRHR guidance for women living with HIV, then reviewed these documents to determine the relevance of existing recommendations that have undergone the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) for inclusion in this consolidated guideline. The SG identified the following eight topic areas for new

---

recommendations or good practice statements: psychosocial support, ageing and healthy sexuality, economic empowerment and resource access (including food security), integration of SRHR and HIV services, empowerment and self-efficacy around safer sex and reproductive decision-making, facilitating safe disclosure for women living with HIV who fear or experience violence, modes of delivery for best maternal and perinatal outcomes (specifically caesarean section), and safe medical and surgical abortion. Development of the new recommendations and good practice statements to respond to these eight topic areas began with systematic and narrative reviews of the evidence. The Guideline Development Group (GDG) assessed the quality of the available evidence for the new recommendations and considered the benefits and risks, values and preferences, human rights, equity, costs and feasibility of implementation to determine the strength of each recommendation.

Creating an enabling environment

Implementing comprehensive and integrated SRHR and HIV programmes to meet the health needs and rights of the diverse group of women living with HIV requires that interventions be put into place to overcome barriers to service uptake, use and continued engagement. In all epidemic contexts, these barriers occur at the individual, interpersonal, community and societal levels. They may include challenges such as social exclusion and marginalization, criminalization, stigma, gender-based violence and gender inequality, among others. Strategies are needed across health system building blocks to improve the accessibility, acceptability, affordability, uptake, equitable coverage, quality, effectiveness and efficiency of services for women living with HIV. If left unaddressed, such barriers undermine health interventions and the SRHR of women living with HIV.

Implementation and updating of the guideline

Action on the recommendations in this guideline requires a strategy that is informed by evidence, appropriate to the local context, and responsive to the needs and rights of women living with HIV. In addition, programmes should aim to achieve equitable health outcomes, promote gender equality, and deliver the highest-quality care efficiently at all times. Effective implementation of the recommendations and good practice statements in this guideline will likely require reorganization of care and redistribution of health-care resources, particularly in low- and middle-income countries. Potential barriers are noted and a phased approach to adoption, adaptation and implementation of the guideline recommendations is advised.

During the guideline development process, the GDG identified important knowledge gaps that need to be addressed through primary research. This guideline will be updated five years after publication unless significant new evidence emerges that necessitates earlier revision.

Tables 1 and 2 present the new and existing recommendations and good practice statements, respectively. Figure 1 presents a visual framework that brings together all the elements of the guideline, with women living with HIV (and their expressed values and preferences) at the core.
Table 1: Summary list of WHO recommendations for the sexual and reproductive health and rights (SRHR) of women living with HIV

Note: Where recommendations apply to “key populations” this includes women living with HIV and therefore these have been included in these guidelines.

<table>
<thead>
<tr>
<th>A. Creating an enabling environment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Healthy sexuality across the life course</strong></td>
</tr>
<tr>
<td><strong>REC A.1:</strong> Adolescent-friendly health services should be implemented in HIV services to ensure engagement and improved outcomes.¹</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Integration of SRHR and HIV services</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>REC A.2:</strong> In generalized epidemic settings, antiretroviral therapy (ART) should be initiated and maintained in eligible pregnant and postpartum women and in infants at maternal and child health care settings, with linkage and referral to ongoing HIV care and ART, where appropriate.</td>
</tr>
<tr>
<td><strong>REC A.3:</strong> Sexually transmitted infection (STI) and family planning services can be integrated within HIV care settings.</td>
</tr>
<tr>
<td><strong>REC A.4, A.5 and A.6:</strong> Decentralization of HIV treatment and care should be considered as a way to increase access to and improve retention in care:</td>
</tr>
<tr>
<td>– initiation of ART in hospitals with maintenance of ART in health facilities;</td>
</tr>
<tr>
<td>– initiation and maintenance of ART in peripheral health facilities;</td>
</tr>
<tr>
<td>– initiation of ART at peripheral health facilities with maintenance at the community level.</td>
</tr>
<tr>
<td><strong>REC A.7:</strong> Trained and supervised lay providers can distribute ART to adults, adolescents and children living with HIV.</td>
</tr>
<tr>
<td><strong>REC A.8:</strong> Trained non-physician clinicians, midwives and nurses can initiate first-line ART.</td>
</tr>
<tr>
<td><strong>REC A.9:</strong> Trained non-physician clinicians, midwives and nurses can maintain ART.</td>
</tr>
<tr>
<td><strong>REC A.10:</strong> Trained and supervised community health workers can dispense ART between regular clinical visits.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Protection from violence and creating safety</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>REC A.11:</strong> Women who disclose any form of violence by an intimate partner (or other family member) or sexual assault by any perpetrator should be offered immediate support. Health-care providers should, as a minimum, offer first-line support when women disclose violence. If health-care providers are unable to provide first line support, they should ensure that someone else (within their health-care setting or another that is easily accessible) is immediately available to do so.²</td>
</tr>
<tr>
<td><strong>REC A.12:</strong> Health-care providers should ask about exposure to intimate partner violence when assessing conditions that may be caused or complicated by intimate partner violence, in order to improve diagnosis/identification and subsequent care.</td>
</tr>
</tbody>
</table>

---


**Executive summary**

**REC A.13:** In-service training and training at pre-qualification level and in first-line support for women who have experienced intimate partner violence and sexual assault should be provided to health-care providers (in particular doctors, nurses and midwives).

**REC A.14:** Pregnant women who disclose intimate partner violence should be offered brief to medium-duration empowerment counselling (up to 12 sessions) and advocacy/support, including a safety component, offered by trained service providers where health-care systems can support this. The extent to which this may apply to settings outside of antenatal care, or its feasibility in low- or middle-income countries, is uncertain.

**REC A.15:** Care for women experiencing intimate partner violence and sexual assault should, as much as possible, be integrated into existing health services rather than as a stand-alone service.

**REC A.16:** Mandatory reporting of intimate partner violence to the police by the health-care provider is not recommended. However, health-care providers should offer to report the incident to the appropriate authorities (including the police) if the woman wants this and is aware of her rights.

**Community empowerment**

**REC A.17:** Provide free HIV and tuberculosis (TB) treatment for health workers in need facilitating the delivery of these services in a non-stigmatizing, gender-sensitive, confidential, and convenient setting when there is no staff clinic and/or their own facility does not offer ART, or where health workers prefer services off-site.³

**REC A.18:** Introduce new, or reinforce existing, policies that prevent discrimination against health workers with HIV or TB, and adopt interventions aimed at stigma reduction among colleagues and supervisors.⁴

<table>
<thead>
<tr>
<th>Recommendation (REC)</th>
<th>Strength of recommendation, quality of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sexual health counselling and support</strong></td>
<td></td>
</tr>
<tr>
<td><strong>REC B.1 (NEW):</strong> WHO recommends that for women living with HIV, interventions on self-efficacy and empowerment around sexual and reproductive health and rights should be provided to maximize their health and fulfil their rights.</td>
<td>Strong recommendation, low-quality evidence</td>
</tr>
<tr>
<td><strong>REC B.2:</strong> Brief sexuality-related communication (BSC) is recommended for the prevention of sexually transmitted infections among adults and adolescents in primary health services.⁵</td>
<td>Strong recommendation, low-to moderate-quality evidence</td>
</tr>
<tr>
<td><strong>REC B.3:</strong> Training of health-care providers in sexual health knowledge and in the skills of BSC is recommended.⁶</td>
<td>Strong recommendation, low-to very low-quality evidence</td>
</tr>
</tbody>
</table>

---


⁴. Ibid.


⁶. Ibid.
### Violence against women services

**REC B.4 (NEW):** WHO recommends that policy-makers and service providers who support women living with HIV who are considering voluntary HIV disclosure should recognize that many fear, or are experiencing, or are at risk of intimate partner violence.

**REC B.5 (NEW):** WHO recommends that interventions and services supporting women living with HIV who are considering voluntary HIV disclosure should include discussions about the challenges of their current situation, the potential associated risk of violence, and actions to disclose more safely, and facilitate links to available violence prevention and care services.

**REC B.6:** Adolescents should be counselled about the potential benefits and risks of disclosure of their HIV status to others and empowered and supported to determine if, when, how and to whom to disclose.\(^7\)

**REC B.7:** HIV testing services for couples and partners, with support for mutual disclosure, should be offered to individuals with known HIV status and their partners.\(^8\)

**REC B.8:** Initiatives should be put in place to enforce privacy protection and institute policy, laws and norms that prevent discrimination and promote tolerance and acceptance of people living with HIV. This can help create environments where disclosure of HIV status is easier.\(^9\)

**REC B.9:** Children of school age* should be told their HIV positive status; younger children should be told their status incrementally to accommodate their cognitive skills and emotional maturity, in preparation for full disclosure.\(^10\)

**REC B.10:** Children of school age* should be told the HIV status of their parents or caregivers; younger children should be told this incrementally to accommodate their cognitive skills and emotional maturity.\(^11\)

---

* In the document, school-age children are defined as those with the cognitive skills and emotional maturity of a normally developing child of 6–12 years.

---


10. Ibid.

11. Ibid.
<table>
<thead>
<tr>
<th>Family planning and infertility services</th>
</tr>
</thead>
</table>
| **REC B.11:** In countries where HIV transmission occurs among serodiscordant couples, where discordant couples can be identified and where additional HIV prevention choices for them are needed, daily oral PrEP (specifically tenofovir or the combination of tenofovir and emtricitabine) may be considered as a possible additional intervention for the uninfected partner.  

**Conditional recommendation, high-quality evidence** |
| **REC B.12:** ART should be initiated in all adults living with HIV, regardless of WHO clinical stage and at any CD4 cell count.  

**Strong recommendation, moderate-quality evidence** |
| **REC B.13:** The correct and consistent use of condoms with condom-compatible lubricants is recommended for all key populations to prevent sexual transmission of HIV and sexually transmitted infections (STIs).  

**Strong recommendation, moderate-quality evidence** |
| **REC B.14:** Women living with asymptomatic or mild HIV clinical disease (WHO stage 1 or 2) can use the following hormonal contraceptive methods without restriction: combined oral contraceptive pills (COCs), combined injectable contraceptives (CICs), contraceptive patches and rings, progestogen-only pills (POPs), progestogen-only injectables (POIs; depot medroxyprogesterone acetate [DMPA] and norethisterone enanthate [NET-EN]), and levonorgestrel (LNG) and etonogestrel (ETG) implants (MEC Category 1). Women living with asymptomatic or mild HIV clinical disease (WHO stage 1 or 2) can generally use the LNG-IUD (MEC Category 2) (Part I, section 12b).  

**Strength of recommendation is indicated by MEC category, which is noted in text.**  

**Moderate- to very low-quality evidence** |
| **REC B.15:** Women living with severe or advanced HIV clinical disease (WHO stage 3 or 4) can use the following hormonal contraceptive methods without restriction: COCs, CICs, contraceptive patches and rings, POIs (DMPA and NET-EN), and LNG and ETG implants (MEC Category 1). Women living with severe or advanced HIV clinical disease (WHO stage 3 or 4) should generally not initiate use of the LNG-IUD (MEC Category 3 for initiation) until their illness has improved to asymptomatic or mild HIV clinical disease (WHO stage 1 or 2). However, women who already have an LNG-IUD inserted and who develop severe or advanced HIV clinical disease need not have their IUD removed (MEC Category 2 for continuation). LNG-IUD users with severe or advanced HIV clinical disease should be closely monitored for pelvic infection (Part I, section 12c).  

**Low- to very low-quality evidence** |
| **REC B.16:** Women taking any nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) can use all hormonal contraceptive methods without restriction: COCs, CICs, contraceptive patches and rings, POIs, POIs (DMPA and NET-EN), and LNG and ETG implants (MEC Category 1). Women living with severe or advanced HIV clinical disease (WHO stage 3 or 4) can generally use the LNG-IUD (MEC Category 1) (Part I, section 12d).  

**Low- to very low-quality evidence** |
| **REC B.17:** Women using ART containing either efavirenz or nevirapine can generally use COCs, patches, rings, CICs, POIs, NET-EN and implants (MEC Category 2). However, women using efavirenz or nevirapine can use DMPA without restriction (MEC Category 1) (Part I, section 12d).  

**Low- to very low-quality evidence** |

16. MEC categories (Medical eligibility criteria for contraceptive use, fifth edition, WHO, 2015):  

1. A condition for which there is no restriction for the use of the contraceptive method  
2. A condition where the advantages of using the method generally outweigh the theoretical or proven risks  
3. A condition where the theoretical or proven risks usually outweigh the advantages of using the method  
4. A condition which represents an unacceptable health risk if the contraceptive method is used.
**REC B.18:** Women using the newer non-nucleoside/nucleotide reverse transcriptase inhibitors (NNRTIs), etravirine and rilpivirine, can use all hormonal contraceptive methods without restriction (MEC Category 1) (Part I, section 12d).

**REC B.19:** Women using protease inhibitors (e.g. ritonavir and antiretrovirals [ARVs] boosted with ritonavir) can generally use COCs, contraceptive patches and rings, CICs, POPs, NET-EN, and LNG and ETG implants (MEC Category 2), and can use DMPA without restriction (MEC Category 1) (Part I, section 12d).

**REC B.20:** Women using the integrase inhibitor raltegravir can use all hormonal contraceptive methods without restriction (MEC Category 1) (Part I, section 12d).

**REC B.21:** Intrauterine device (IUD): Women using ARV medication can generally use LNG-IUDs (MEC Category 2), provided that their HIV clinical disease is asymptomatic or mild (WHO stage 1 or 2). Women living with severe or advanced HIV clinical disease (WHO stage 3 or 4) should generally not initiate use of the LNG-IUD (MEC Category 3 for initiation) until their illness has improved to asymptomatic or mild HIV clinical disease. However, women who already have an LNG-IUD inserted and who develop severe or advanced HIV clinical disease need not have their IUD removed (MEC Category 2 for continuation). LNG-IUD users with severe or advanced HIV clinical disease should be closely monitored for pelvic infection (Part I, section 12d).

### Antenatal care and maternal health services

**REC B.22 (NEW):** WHO recommends that elective caesarean section (C-section) should not be routinely recommended to women living with HIV.

**REC B.23:** Late cord clamping (performed approximately 1–3 minutes after birth) is recommended for all births while initiating simultaneous essential newborn care.\(^\text{17}\)

**REC B.24:** ART should be initiated in all adolescents living with HIV, regardless of WHO clinical stage and at any CD4 cell count.\(^\text{18}\)

**REC B.25:** As a priority, ART should be initiated in all adolescents with severe or advanced HIV clinical disease (WHO clinical stage 3 or 4) and adolescents with a CD4 count ≤ 350 cells/mm\(^3\).\(^\text{19}\)

**REC B.26:** ART should be initiated in all pregnant and breastfeeding women living with HIV, regardless of WHO clinical stage and at any CD4 cell count, and continued lifelong.\(^\text{20}\)

**REC B.27:** Mothers living with HIV should breastfeed for at least 12 months and may continue breastfeeding for up to 24 months or longer (similar to the general population) while being fully supported for ART adherence.\(^\text{21}\)

---


\(^\text{19}\). Ibid.

\(^\text{20}\). Ibid.

**Executive summary**

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Grade and Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>REC B.28:</strong> The use of amniotomy alone for prevention of delay in labour is not recommended.</td>
<td>Weak recommendation, very low-quality evidence</td>
</tr>
<tr>
<td><strong>REC B.29:</strong> The use of amniotomy and oxytocin for treatment of confirmed delay in labour is recommended.</td>
<td>Weak recommendation, very low-quality evidence</td>
</tr>
</tbody>
</table>

### Safe abortion services

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Grade and Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>REC B.30 (NEW):</strong> WHO recommends that safe abortion services should be the same for women living with HIV who want a voluntary abortion as for all women.</td>
<td>Strong recommendation, very low-quality evidence</td>
</tr>
<tr>
<td><strong>REC B.31 (NEW):</strong> WHO suggests that women living with HIV who want a voluntary abortion can be offered a choice of medical or surgical abortion, as for all women.</td>
<td>Conditional recommendation, very low-quality evidence</td>
</tr>
</tbody>
</table>

### Sexually transmitted infection and cervical cancer services

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Grade and Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>REC B.32:</strong> Sexually transmitted infection (STI) and family planning services can be integrated within HIV care settings.</td>
<td>Conditional recommendation, very low-quality evidence</td>
</tr>
<tr>
<td><strong>REC B.33:</strong> WHO recommends the human papillomavirus (HPV) vaccine for girls in the age group of 9–13 years. Girls receiving a first dose of HPV vaccine before the age of 15 years can use a two-dose schedule. The interval between the two doses should be six months. There is no maximum interval between the two doses; however, an interval of no greater than 12–15 months is suggested. If the interval between doses is shorter than five months, then a third dose should be given at least six months after the first dose. Immunocompromised individuals, including those who are living with HIV, and females aged 15 years and older should also receive the vaccine and need three doses (at 0, 1–2, and 6 months) to be fully protected.</td>
<td>No details on strength or quality found, but recommendation is based on the GRADE approach</td>
</tr>
</tbody>
</table>

---


23. Ibid.


Table 2: Summary list of WHO good practice statements for the sexual and reproductive health and rights (SRHR) of women living with HIV

Note: Where good practice statements apply to “key populations” this includes women living with HIV and therefore these have been included in these guidelines.

### A. Creating an enabling environment: Good practice statements (GPS)

#### Psychosocial support

GPS A.1 *(NEW)*: Psychosocial support interventions, such as support groups and peer support, provided by, with, and for women living with HIV, should be included in HIV care.

#### Healthy sexuality across the life course

GPS A.2 *(NEW)*: Women living with HIV in all their diversity should be supported in their choice to have safe and fulfilling sexual relationships and sexual pleasure as they age. Women living with HIV who choose not to be sexually active should also be supported in their choice.

#### Economic empowerment and resource access

GPS A.3 *(NEW)*: Comprehensive assessment of food security with linkage to appropriate services is an integral component of the care of women living with HIV.

#### Integration of SRHR and HIV services

GPS A.4 *(NEW)*: Women living with HIV should have access to integrated and tailored comprehensive* sexual and reproductive health (SRH) and HIV services.

GPS A.5 *(NEW)*: Women living with HIV should be included in the design and delivery of these services.

*As defined in the WHO Global Reproductive Health Strategy, 2004

#### Protection from violence and creating safety

GPS A.6: Violence against people from key populations should be prevented and addressed in partnership with key population-led organizations. All violence against people from key populations should be monitored and reported, and redress mechanisms should be established to provide justice.27

GPS A.7: Health and other support services should be provided to all persons from key populations who experience violence. In particular, persons experiencing sexual violence should have timely access to comprehensive post-rape care in accordance with WHO guidelines.

GPS A.8: Law enforcement officials and health- and social-care providers need to be trained to recognize and uphold the human rights of key populations and to be held accountable if they violate these rights, including perpetration of violence.

#### Social inclusion and acceptance

GPS A.9: Policy-makers, parliamentarians and other public health leaders should work together with civil society organizations in their efforts to monitor stigma, confront discrimination against key populations and change punitive legal and social norms.

GPS A.10: Health-care workers should receive appropriate recurrent training and sensitization to ensure that they have the skills, knowledge and understanding to provide services for adults and adolescents from key populations based on all persons’ right to health, confidentiality and non-discrimination.

GPS A.11: It is recommended to make contraceptives affordable to all, including adolescents, and that law and policy support access to contraception for disadvantaged and marginalized populations.


### Executive summary

**Community empowerment**

**GPS A.12:** Programmes should be put in place to provide legal literacy and legal services to key populations so that they know their rights and applicable laws and can receive support from the justice system when aggrieved.

**Supportive laws and policies and access to justice**

**GPS A.13:** Countries should work towards decriminalization of behaviours such as drug use/injecting, sex work, same-sex activity and nonconforming gender identities, and towards elimination of the unjust application of civil law and regulations against people who use/inject drugs, sex workers, men who have sex with men and transgender people.

**GPS A.14:** Countries should work towards developing non-custodial alternatives to incarceration of drug users, sex workers and people who engage in same-sex activity.

**GPS A.15:** Countries are encouraged to examine their current consent policies and consider revising them to reduce age-related barriers to HIV services and to empower providers to act in the best interest of the adolescent.

**GPS A.16:** It is recommended that sexual and reproductive health services, including contraceptive information and services, be provided for adolescent girls without mandatory parental and guardian authorization/ notification.

**GPS A.17:** Countries should work towards developing policies and laws that decriminalize same-sex behaviours and nonconforming gender identities.

**GPS A.18:** Countries should work towards legal recognition for transgender people.

**GPS A.19:** For transgender people the legal recognition of preferred gender and name may be important to reduce stigma, discrimination and ignorance about gender variance. Such recognition by health services can support better access, uptake and provision of HIV services.

### B. Health interventions: Good practice statements (GPS)

#### Brief sexuality communication (BSC)

**GPS B.1:** Health policy-makers and decision-makers in health-care professional training institutions need to ensure that, where BSC is introduced, it respects, protects and fulfils clients’ human rights.\(^{28}\)

#### Contraception

**GPS B.2:** It is recommended that third-party authorization requirements be eliminated, including spousal authorization requirements for women living with HIV for obtaining contraceptives and related information and services.\(^{29}\)

#### Prevention of perinatal transmission of HIV

**GPS B.3:** Mothers living with HIV and health-care workers can be reassured that ART reduces the risk of postnatal HIV transmission in the context of mixed feeding. Although exclusive breastfeeding is recommended, practising mixed feeding is not a reason to stop breastfeeding in the presence of ARV drugs.\(^{30}\)

---

Figure 1: Framework of WHO recommendations and good practice statements to advance the sexual and reproductive health and rights of women living with HIV

This framework illustrates the essential structure of this consolidated guideline and points the reader to specific topics and relevant WHO recommendations (REC) and good practice statements (GPS). The values and preferences of women living with HIV, as expressed by respondents in the Global Values and Preferences Survey, are at the core of this guideline, which is grounded in and advocates for a comprehensive, woman-centred approach to SRHR, and is underpinned by the guiding principles of gender equality and human rights (represented in the pink circle). With this as a foundation, the framework then shows: (A) the encompassing enabling environment (outer purple circle), with all the eight topics as presented in Chapter 3 of the full guideline document (starting at the top and running clockwise); and (B) the health interventions (central teal segments), with all six topics as presented in Chapter 4 of the full guideline document (also clockwise from the top) – in all cases, these topics are accompanied by information on the relevant numbered RECs and GPSs, which are also listed in Tables 1 and 2, respectively.